ethosuximide has been researched along with propranolol in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Budziszewska, B; Koczurkiewicz, P; Marona, H; Pańczyk, K; Pękala, E; Piska, K; Pytka, K; Rapacz, A; Starek-Świechowicz, B; Waszkielewicz, AM | 1 |
| Rane, A; Wilson, JT | 1 |
| Lasek, R; Müller, M | 1 |
| Müller, FO; Steyn, JM | 1 |
| Leigh, RJ; Miura, K; Optican, LM; Ramat, S; Shaikh, AG; Zee, DS | 1 |
| Abe, K; Hashimura, M; Iha, HA; Iwai, C; Kato, M; Kawaji, S; Kawakita, K; Kunisawa, N; Ogawa, M; Ohno, Y; Shimizu, S | 1 |
1 review(s) available for ethosuximide and propranolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for ethosuximide and propranolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design, synthesis and anticonvulsant-analgesic activity of new
Topics: | 2017 |
Clinical pharmacokinetics in infants and children.
Topics: Aging; Body Water; Carbamazepine; Child; Child, Preschool; Clindamycin; Dextropropoxyphene; Diazoxide; Dicloxacillin; Digoxin; Ethosuximide; Humans; Infant; Infant, Newborn; Kidney; Kinetics; Pharmaceutical Preparations; Phenobarbital; Phenytoin; Propranolol; Sulfonamides; Tetracycline; Theophylline | 1976 |
[The anticonvulsant action of propranolol in pentylenetetrazole-induced convulsions].
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Ethosuximide; Male; Mice; Pentylenetetrazole; Phenobarbital; Propranolol | 1985 |
Comparative effects of two commercially available blood collection tubes on plasma concentrations of drugs.
Topics: Acebutolol; Blood Specimen Collection; Carbamazepine; Diazepam; Digoxin; Ethosuximide; Humans; Nordazepam; Penbutolol; Pharmaceutical Preparations; Propranolol; Quinidine; Salicylates; Time Factors; Valproic Acid; Warfarin | 1980 |
The effects of ion channel blockers validate the conductance-based model of saccadic oscillations.
Topics: Case-Control Studies; Ethosuximide; Humans; Ion Channels; Models, Biological; Models, Neurological; Neurons; Ocular Motility Disorders; Propranolol; Saccades; Syndrome; Tremor | 2011 |
Pharmacological characterization of nicotine-induced tremor: Responses to anti-tremor and anti-epileptic agents.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Benzeneacetamides; Calcium Channel Blockers; Carbamazepine; Diazepam; Disease Models, Animal; Essential Tremor; Ethosuximide; Male; Mice, Inbred Strains; Nicotine; Phenobarbital; Propranolol; Pyridines; Valproic Acid | 2018 |